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Toxicity-dependent feasibility bounds for
the escalation with overdose control
approach in phase I cancer trials
Graham M. Wheeler,a,b*† Michael J. Sweetingc and
Adrian P. Manderb
Phase I trials of anti-cancer therapies aim to identify a maximum tolerated dose (MTD), defined as the dose that
causes unacceptable toxicity in a target proportion of patients. Both rule-based and model-based methods have
been proposed for MTD recommendation. The escalation with overdose control (EWOC) approach is a model-
based design where the dose assigned to the next patient is one that, given all available data, has a posterior
probability of exceeding the MTD equal to a pre-specified value known as the feasibility bound. The aim is to
conservatively dose-escalate and approach the MTD, avoiding severe overdosing early on in a trial. The EWOC
approach has been applied in practice with the feasibility bound either fixed or varying throughout a trial, yet
some of the methods may recommend incoherent dose-escalation, that is, an increase in dose after observing
severe toxicity at the current dose. We present examples where varying feasibility bounds have been used in
practice, and propose a toxicity-dependent feasibility bound approach that guarantees coherent dose-escalation
and incorporates the desirable features of other EWOC approaches. We show via detailed simulation studies
that the toxicity-dependent feasibility bound approach provides improved MTD recommendation properties to
the original EWOC approach for both discrete and continuous doses across most dose-toxicity scenarios, with
comparable performance to other approaches without recommending incoherent dose escalation. © 2017 The
Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
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1. Introduction
Phase I clinical trials mark the first experimentation of a new drug in a human population. For cyto-
toxic anti-cancer drugs, the aim of a phase I trial is to gradually adapt the dose level of the drug given to
patients in order to identify the Maximum Tolerated Dose (MTD) of the experimental treatment. Various
definitions for the MTD exist [1], but it is commonly regarded as the largest dose that leads to unaccept-
able toxicity in a target proportion, 𝜃, of patients [2]. The rationale for targeting such a dose is based on
the assumption that higher doses will be more effective, yet more toxic [3], and that toxicity is tolera-
ble for optimal anti-tumour activity [4]. Commonly, toxicity frequency and severity data are reduced to
a single binary outcome, which denotes whether a dose-limiting toxicity (DLT) has occurred or not [1].
Therefore, for a pre-specified target toxicity level (TTL) of 𝜃, the definition of the MTD can be expressed
mathematically as
P (DLT | dose = MTD) = 𝜃. (1)
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The traditional approach for performing phase I dose-escalation studies has long been the 3+3 design
[5, 6], which remains popular in practice [1, 7, 8], despite having several pitfalls including slow dose-
escalation, not using all trial data to make dose-escalation decisions, not having a pre-determined target,
poor MTD identification properties and no statistical justification [9–15]. In order to overcome such
pitfalls, several novel model-based designs have been proposed. The Escalation with Overdose Control
(EWOC) approach [4] is a Bayesian adaptive design that aims to reduce the risk of overdosing patients by
choosing doses with a posterior probability of being above the trueMTD equal to some value known as the
feasibility bound. The feasibility bound, denoted as 𝛼, controls how conservative dose-escalation is and
was originally suggested to be a fixed constant throughout the trial. Several publications [16–18] describe
trials where 𝛼 increases during the trial so that eventually dose selection is based on the posterior median
of the MTD distribution. Whilst such a design provides improved operating characteristics relative to the
original EWOC approach with a fixed feasibility bound [19], there is no guarantee of dose-escalation that
is coherent [20–22]; that is, dose escalation may be recommended despite having observed a DLT in the
previous patient [23].
In this paper, we describe and investigate an approach for increasing the feasibility bound during a trial
using the EWOC approach that guarantees coherent dose-escalation behaviour and has comparable oper-
ating characteristics to other methods that have been implemented in practice. Section 2 describes the
EWOC dose-escalation approach, previously used adaptive feasibility bounds and outlines the proposed
approach, which is dependent on the number of non-DLT responses observed in the trial; we refer to this
as the toxicity-dependent feasibility bound (TDFB) approach. In Section 3, we describe a comprehen-
sive simulation study comparing the TDFB approach to other EWOC-based approaches, and Section 4
presents the results of this study and sensitivity analyses assuming misspecification of the dose-toxicity
model. We conclude with a discussion of the findings and limitations of our approach in Section 5 and
offer recommendations for future trials.
2. Methods
2.1. Escalation with overdose control
Let Yi be a binary random variable such that Yi = 1 if patient i experiences a DLT and Yi = 0 otherwise.
For a dose range bounded below by xmin and above by xmax, denote the probability of DLT for patient i at
dose level x ∈
[
xmin, xmax
]
by 𝜋 (x; 𝜷), where 𝜷 is a parameter vector. Several structural forms for 𝜋 (x; 𝜷)
have been proposed [21], but we shall only consider the two-parameter logistic model proposed in the
original EWOC paper [4], that is,
P
(
Yi = 1 | dose = x) = 𝜋 (x; 𝛽0, 𝛽1) = exp
(
𝛽0 + 𝛽1x
)
1 + exp
(
𝛽0 + 𝛽1x
) , (2)
where 𝛽0 and 𝛽1 are parameters to be estimated, with the assumption that 𝛽1 > 0 to ensure the assumption
ofmonotonicity is satisfied.Wemay rearrange equation 2 using equation 1 to show that theMTD, denoted
as 𝛾 , can be written as
𝛾 =
logit (𝜃) − 𝛽0
𝛽1
. (3)
Under the original EWOC approach [4], the form of 𝜋
(
x; 𝛽0, 𝛽1
)
may be expressed in terms of two
clinically relevant and interpretable parameters: the MTD 𝛾 as defined in equation 3; and the probability
of DLT at the lowest dose level to be used in the trial, denoted as 𝜌0, that is,
𝜌0 = 𝜋
(
xmin; 𝛽0, 𝛽1
)
=
exp
(
𝛽0 + 𝛽1xmin
)
1 + exp
(
𝛽0 + 𝛽1xmin
) . (4)
These parameters are more meaningful to clinicians and can be used in the Bayesian updating procedure
by placing prior distributions on 𝛾 and 𝜌0 [4, 24]. Babb et al. [4] suggest a Uniform prior distribution
for 𝛾 over the interval
[
xmin, xmax
]
, and a Uniform prior distribution for 𝜌0 over the interval [0, 𝜃], since
𝜌0 > 𝜃 implies that the MTD 𝛾 is lower than xmin. Alternative prior distributions for 𝛾 and 𝜌0 have been
investigated, which either induce a particular correlation structure between 𝛾 and 𝜌0, or do not truncate
the domain of 𝛾 from above [25].
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Subsequent calculations are conditional on the event Y1 = 0, that is, the first patient did not experience
a DLT. If Y1 = 1, it is recommended that the trial is suspended for safety concerns and the dose range re-
evaluated, or the trial is terminated [4,18,25]. Given observed trial dataDn =
{(
x(i), yi
)
∶ i = 1,… , n
}
,
where patient i ∈ {1,… , n} received dose x(i) ∈
[
xmin, xmax
]
and had outcome yi recorded, and a joint
prior distribution f
(
𝛾, 𝜌0
)
for parameters 𝛾 and 𝜌0, themarginal posterior cumulative distribution function
for the MTD is
Hn(𝛾 ′) = P(𝛾 ⩽ 𝛾 ′ |Dn) = ∫ 𝛾
′
xmin
∫
𝜃
0
g(𝛾, 𝜌0 |Dn) d𝜌0 d𝛾
= ∫
𝛾 ′
xmin
∫
𝜃
0
L(𝛾, 𝜌0 |Dn)f (𝛾, 𝜌0)
∫ xmaxxmin ∫ 𝜃0 L(𝛾, 𝜌0 |Dn)f (𝛾, 𝜌0) d𝜌0 d𝛾 d𝜌0 d𝛾,
(5)
where L(𝛾, 𝜌0 |Dn) = ∏ni=1 𝜋(x; 𝛾, 𝜌0)yi(1 − 𝜋(x; 𝛾, 𝜌0))1−yi is the likelihood and g(𝛾, 𝜌0 |Dn) is the joint
posterior distribution function for 𝛾 and 𝜌0.
Under the EWOC approach, dose allocation for the next cohort of patients is determined by selecting
a specified percentile from the posterior MTD distribution. The percentile of choice, known as the feasi-
bility bound and denoted as 𝛼, governs the degree of conservatism present in the trial. Assuming a cohort
size of one patient, the dose for the (n + 1)th patient is
x (n + 1) = H−1n (𝛼) . (6)
The feasibility bound can be interpreted via a decision-theoretic loss function as the relative preference of
underdosing a patient compared to overdosing a patient. For any 𝛿 > 0, the loss incurred by overdosing
a patient (with respect to the MTD 𝛾) by 𝛿 units is 1−𝛼
𝛼
times greater than underdosing a patient by 𝛿
units [4, 16].
Different proposals have been made for choosing an MTD at the end of the trial. Babb et al. [4] sug-
gest the recommended MTD should be the posterior mean of the MTD distribution, although in clinical
practice, it is often the case that the MTD is the dose that would be given if a new patient were recruited
into the trial. Berry et al. [26] estimate the MTD by a central estimate of the posterior MTD distribution
(either mean, median or mode), and in a time-to-event adaptation of the EWOC approach, Tighiouart
et al. [27] select the posterior median of the MTD distribution at the end of the trial.
2.2. Varying the feasibility bound
Under the EWOC approach with fixed 𝛼 and uniform prior on 𝛾 , the dose for the second patient is
the 100𝛼th percentile of the dose range
[
xmin, xmax
]
. Clinicians may consider this dose recommenda-
tion too high to administer to a patient early on in the trial [28] and prefer to conservatively escalate
the dose at first, and then gradually relax the overdose control as more data are accrued. This combines
the approaches of escalating as quickly as possible to the MTD, whilst simultaneously retaining some
degree of overdose control. The idea of changing the feasibility bound during the trial has been discussed
[2, 16, 19] and used in practice [16–18]. At the start of the trial, 𝛼 is set to some minimal level strictly
less than 0.50, so that the first patients are treated at safe doses. As data accrue and the precision of the
MTD distribution increases, 𝛼 is gradually increased towards 0.50, at which point all future patients will
be treated at the posterior median estimate of the MTD distribution. Allowing 𝛼 to increase towards 0.50
also overcomes a concern raised by Berry et al. [26] that when 𝛼 is fixed at some level below 0.50, the
MTD estimated using the mean or median of 𝛾 may be much larger than any dose given to patients during
the trial.
Chu et al. [19] proposed a varying feasibility bound approach, which they called the Hybrid design;
for a trial of fixed sample size N, 𝛼 is initially set at some minimum, denoted 𝛼min, and increased in
a stepwise manner so that it reaches 0.50 after patient N∕2. They showed via simulation studies that
the Hybrid design gave comparable operating characteristics to the modified Continual Reassessment
Method (CRM) [29,30], and both of these approaches were better at identifying the correct MTD relative
to the conventional EWOC approach with fixed 𝛼.
However, whilst increasing the feasibility bound in a step-wise procedure can provide a desirable blend
between conservative dose-escalation at the start of a trial with reaching the true MTD quicker than
the original EWOC approach, a problem still remains. If the feasibility bound is increased, despite the
most recent patient experiencing a DLT, the recommendation may be to treat the next patient at a higher
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dose level. Investigators and clinicians would prefer to have a trial design that can guarantee coherent
dose-escalation [20] as well as offer favourable experimentation and MTD recommendation properties.
A trial design that is coherent will never recommend a dose higher than the previous patient’s dose if the
previous patient experienced a DLT, nor recommend a dose lower than the previous patient’s dose if the
previous patient did not experience a DLT [21]. The unmodified CRM approach has been shown to be
coherent [20,21,31], and the EWOC approach is coherent for n ⩾ 2 [18]. However, if increases in 𝛼 occur
regardless of the DLT response of the preceding patients, an incoherent dose-escalation, or coherence
violation, may occur [23]. Bartroff and Lai [22] considered coherence violations in their evaluation of
the EWOC approach with a linearly increasing feasibility bound; their approach to prevent incoherence
was to restrict the choice of dose level to be from either above or below the previous dose if the previous
patient did not or did experience a DLT respectively.
2.3. A toxicity-dependent feasibility bound
We now present an approach for varying the feasibility bound that guarantees coherent dose escalation.
The method also provides less conservative escalation when no DLT is observed at the current patient
compared to a linearly increasing feasibility bound, such as that used in the Hybrid design. The TDFB
to determine the dose given to patient n + 1 is
𝛼n+1 = min
{
0.50, 𝛼min +
(
0.50 − 𝛼min
) (n − 1 −∑ni=1 yi)
S
}
, (7)
where
(
n − 1 −
∑n
i=1 yi
)
is the number of patients not experiencing DLTs out of the n− 1 patients dosed
after patient 1 (since if y1 = 1, we stop the trial due to safety concerns) and S is a strictly positive constant
chosen before the trial. This feasibility bound is non-decreasing, has a value of 𝛼min when n = 1 (i.e.
𝛼2 = 𝛼min) and does not exceed 0.50. The constant S determines the speed at which 𝛼n increases with n
and can be interpreted as the number of non-DLT responses one must observe (excluding the first patient)
before the posterior median of the MTD distribution can be used for dose selection. To choose a sensible
value for S, consider the expectation of 𝛼n+1 and the patient number for which 𝛼n+1 is expected to first
reach 0.50. Ignoring the minimum aspect of equation 7, the expectation of 𝛼n+1 is
E
(
𝛼n+1
)
= E
(
𝛼min +
(
0.50 − 𝛼min
) (n − 1 −∑ni=1 Yi)
S
)
= 𝛼min +
(
0.50 − 𝛼min
) (n − 1 − E (∑ni=1 Yi))
S
.
(8)
Since we are choosing a value of S before the trial begins, the DLT outcomes of patients i = 1,… , n are
unobserved random variables Yi, rather than observed outcomes yi. In dose finding trials where the goal
is to treat patients at the dose with probability of DLT equal to 𝜃, the long-run expectation of
∑n
i=1 Yi is
(n− 1)𝜃, that is, we expect on average (n− 1)𝜃 DLTs in (n− 1) patients. Therefore, setting E(
∑n
i=1 Yi) =
(n − 1)𝜃 gives
E
(
𝛼n+1
)
= 𝛼min +
(
0.50 − 𝛼min
)( (n − 1) (1 − 𝜃)
S
)
. (9)
One can use equation 9 to decide after how many patients, on average, the feasibility bound should reach
0.50. For example, if we wish the expectation of 𝛼n+1 to be 0.50 when half of N available patients have
been dosed, we can set n = N
2
and E
(
𝛼 N
2
+1
)
= 0.50 so that
E
(
𝛼 N
2
+1
)
= 0.50 = 𝛼min +
(
0.50 − 𝛼min
)( (N2 − 1) (1 − 𝜃)
S
)
⇒ S =
(N
2
− 1
)
(1 − 𝜃) .
(10)
Therefore, one may select S as a function of the total number of patients available, N, and the TTL 𝜃. If,
for example, we have N = 40 patients and 𝜃 = 1∕3, then setting S = 122
3
will mean that on average,
𝛼n will first reach 0.50 after 20 of the 40 patients have been observed. If we consider the difference in
expectations of successive feasibility bounds, then
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E(𝛼n+2) − E(𝛼n+1) =
(
1 − E(Yn+1)
) 0.50 − 𝛼min
S
. (11)
Setting S =
(
N
2
− 1
)
(1 − 𝜃), we have
E(𝛼n+2) − E(𝛼n+1) =
1 − E(Yn+1)
1 − 𝜃
0.50 − 𝛼min
N
2
− 1
. (12)
Under the Hybrid design of Chu et al., the rate of increase in successive feasibility bounds is 0.50−𝛼min
N∕2−1
.
Therefore, if E(Yn+1) < 𝜃, then the increase in expectation of the feasibility bound is greater than that
of the Hybrid design. Similarly, if E(Yn+1) > 𝜃, the rate of increase in successive feasibility bounds is
slower than the Hybrid design. These properties are sensible because we wish to be less conservative
when the expected probability of DLT for the next patient is less than 𝜃, and more conservative when the
expected probability of DLT for the next patient is more than 𝜃. Furthermore, conservative dose-escalation
at the start of the trial coupled with quicker escalation to the MTD are still achievable by increasing the
feasibility bound in the absence of DLTs.
The TDFB approach, or any EWOC approach whereby the feasibility bound only increases when the
last patient does not experience a DLT, guarantees coherent dose escalation/de-escalation behaviour. The
proof of this is a simple extension of that for the coherence of the EWOC approach with fixed 𝛼 given by
Tighiouart and Rogatko [18].
3. Simulation study
We describe and conduct a simulation study comparing several EWOC approaches with fixed and adap-
tive feasibility bounds. We consider the trial described by Babb et al. [4] that used the EWOC approach
to find the MTD of 5-fluorouracil (5-FU) when given in combination with 20 mg/m2 leucovorin and
0.5 mg/m2 topotecan to patients with malignant solid tumours, with a TTL 𝜃 of 1
3
. We consider 10 dif-
ferent dose-toxicity scenarios generated from a logistic model using true values for 𝛾 and 𝜌0 (Table I),
which gave steep, shallow and plateauing dose-toxicity curves (Figure 1). Several scenarios have either
the same 𝛾 or 𝜌0 value, so performance differences between scenarios can be assessed relative to these
individual parameters. The EWOC approach has been used in practice to find the MTD over contin-
uous dose intervals and discrete dose sets [28]; therefore, for each scenario specified by 𝛾 and 𝜌0,
we investigate sub-scenarios with (i) a continuous dose interval, with dose selection made across the
entire dose range of LC = [140, 425]mg/m2 and rounded to the nearest integer, and (ii) six discrete
dose levels LD = {150, 200, 250, 300, 350, 400} mg/m2. For each scenario, we simulate 1000 trials of
N = 40 patients.
We use a bivariate normal prior for the intercept and the log-slope parameters 𝛽0 and log(𝛽1) [32]; this
facilitates the use of the R package bcrm [33], which we have tailored to include the adaptive feasibility
bounds of interest. The main reason for using this package is to quickly conduct MCMC computations
used to generate posterior inferences, which we detail in subsection 3.3. The bivariate normal prior used
has parameters 𝜇0 = −2.56, 𝜇1 = −5.32, 𝜎0 = 1.24, 𝜎1 = 0.91 and 𝜌 = −0.90 (see supplementary
material for R code and plot). This corresponds to a prior mean (SD) of 0.20 (0.15) and 254 (477) for 𝜌0
and 𝛾 , respectively. At the end of the trial, we consider two estimators for the MTD; the posterior median
of the MTD distribution ?̂? = H−1N (0.50), and the dose that would be given to a new patient if they were
recruited into the trial ?̃? = H−1N
(
𝛼N+1
)
. This is because we wish to not only compare the performance
of all designs using the same MTD estimator but also acknowledge that in practice when 𝛼 is fixed at a
level well below 0.50, clinicians may be reluctant to use ?̂? and therefore use the next recommended dose
given the current trial data.
3.1. Approaches for comparison
We examine five approaches for dose selection using a feasibility bound 𝛼n:
(1) EWOC – the original EWOC approach with 𝛼 = 0.25 for each trial;
(2) TR design – the Tighiouart and Rogatko design [18], where 𝛼2 = · · · = 𝛼9 = 0.25, 𝛼n = 𝛼n−1+0.05
for n = 10,… , 14 and 𝛼n = 0.50 for future patients;
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Table I. Dose-toxicity scenarios (for both continuous dose interval and
discrete dose settings) used in simulation study. MTDs for discrete
dose scenarios shown in bold.
Continuous dose scenarios
Scenario MTD (𝛾) 𝜌0 P
(
DLT at xmax
)
𝛽0 𝛽1
1 165 0.25 0.97 −3.369 0.016
2 175 0.30 0.60 −1.464 0.004
3 200 0.03 1.00 −9.970 0.046
4 250 0.05 0.95 −5.810 0.020
5 300 0.001 0.98 −12.344 0.039
6 300 0.02 0.86 −6.691 0.020
7 350 0.01 0.67 −7.196 0.019
8 350 0.05 0.53 −4.445 0.011
9 400 0. 001 0.48 −10.253 0.024
10 400 0.03 0.40 −4.975 0.011
Discrete dose scenarios
Scenario
P(DLT)
d1 d2 d3 d4 d5 d6
1 0.28 0.47 0.66 0.82 0.91 0.96
2 0.31 0.36 0.41 0.46 0.52 0.57
3 0.05 0.33 0.84 0.98 1.00 1.00
4 0.06 0.15 0.33 0.58 0.79 0.92
5 0.00 0.01 0.07 0.33 0.78 0.96
6 0.02 0.06 0.16 0.33 0.58 0.79
7 0.01 0.03 0.07 0.16 0.33 0.56
8 0.06 0.09 0.15 0.23 0.33 0.46
9 0.00 0.00 0.01 0.04 0.13 0.33
10 0.03 0.06 0.09 0.15 0.23 0.33
DLT, dose-limiting toxicity; MTD, maximum tolerated dose.
Figure 1. Dose-toxicity scenarios for continuous dose interval (left plot) and discrete doses (right plot) used in
simulation study. Target toxicity level 𝜃 = 0.33 (blue dashed horizontal line). Lines of same colour have the same
probability of dose-limiting toxicity (DLT) at xmin.
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(3) Hybrid design – the feasibility bound begins at 𝛼min and increases in equal increments after each
patient until 𝛼 N
2
+1 = 𝛼21 = 0.50, then all future patients receive the posterior median of the
MTD distribution;
(4) Escalation in the absence of toxicity (EAT) design – the feasibility bound begins at 𝛼min = 0.10
and increases in increments of 0.05 only when the previous patient did not experience a DLT;
(5) TDFB design – the feasibility bound begins at 𝛼min and increases as per equation 7 up to 0.50; for
a trial with N = 40 and 𝜃 = 1
3
, S = 122
3
.
For the Hybrid and TDFB designs, we use both 𝛼min equal to 0.10 and 0.25.
3.2. Trial design
We outline the dose-escalation method for the EWOC approach with a fixed or varying feasibility bound
for a trial of N patients over dose set L, which may be the continuous interval LC or the discrete dose set
LD.
(1) At the start of the trial, dose patient 1 at the lowest dose level xmin. If Y1 = 1, stop the trial.
Otherwise, proceed to (2).
(2) For 1 ⩽ n < N,
(a) Set 𝛼n+1 using the feasibility bound method of choice.
(b) With joint prior distribution f (𝛾, 𝜌0) and likelihood L(𝛾, 𝜌0 |Dn), obtain posterior distribution
g(𝛾, 𝜌0 |Dn) and marginal cumulative distribution function Hn(𝛾).
(c) Treat patient n + 1 at x(n + 1) such that
x(n + 1) = arg min
l∈L
|H−1n (𝛼n+1) − l|, (13)
where 𝛼n+1 is the feasibility bound. This may be equal to some fixed 𝛼 for all n (original
EWOC approach), or non-decreasing with n (TR design, Hybrid design, EAT design and
TDFB design).
(d) Observe Yn+1. Set n = n + 1.
(e) Repeat steps (a) – (d).
(3) If n = N, stop the trial. Obtain HN(𝛾) and MTD estimate 𝛾 (either posterior median ?̂? or next
recommended dose ?̃?).
3.3. Simulation set-up
We simulated 1000 trials for each approach and dose-toxicity scenario using the R package bcrm [33].
Posterior distributions of 𝛽0 and 𝛽1 were updated by MCMC methods in JAGS [34] (called from bcrm),
which were then used to generate the distributions of 𝛾 and 𝜌0. Two Markov chains were run with a burn-
in period of 20 000 iterations, followed by a posterior sample of 20 000 iterations, thinned at every two
iterations. This was adequate for convergence of the Markov chains and for minimal autocorrelation of
the posterior samples. We report the distributions of patient experimentation and final MTD recommen-
dations, and also the mean bias and root mean squared error (RMSE) of the MTD recommendations. The
mean bias and RMSE are respectively defined as
Mean Bias = 1
1000
1000∑
k=1
(
𝛾k − 𝛾
)
and RMSE =
√√√√ 1
1000
1000∑
k=1
(
𝛾k − 𝛾
)2
, (14)
where 𝛾 is the true MTD and 𝛾k is the MTD recommendation (either the posterior median ?̂? or the next
recommended dose ?̃?) at the end of the kth trial.We also summarise the accuracy of each approach inMTD
recommendation using an accuracy index [21], such that the accuracy A of a dose-escalation approach
is defined as
A = 1 − J
∑J
j=1(𝜋(dj) − 𝜃)
2pj∑J
j=1(𝜋(dj) − 𝜃)2
, (15)
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where J is the number of dose levels in the trial, 𝜋(dj) is the true probability of DLT at dose level dj
and pj is the probability that dose level dj is chosen as the MTD at the end of the trial. A maximum
score of A = 1 implies an approach selects the correct MTD all the time, with lower scores implying
lower accuracy.
4. Simulation results
Table II shows the percentage of coherence violations (with standard errors) for approaches that do not
guarantee coherent dose escalation (all approaches not listed guarantee coherence and therefore presented
no violations). In the continuous dose scenarios, coherence violations were observed for the TR and
Hybrid approaches in all scenarios (mean 3.5 mg/m2, range 1−11 mg/m2). The TR approach has a higher
percentage of coherence violations across all scenarios, due to the larger increases in 𝛼n between patients
(TR = 0.05; Hybrid (𝛼min = 0.10) = 0.40∕19 ≈ 0.021; Hybrid (𝛼min = 0.25) = 0.25∕19 ≈ 0.013). For
discrete dose scenarios, there are far fewer coherence violations (0.005 – 0.02%); much larger increases
in 𝛼n are required for an approach to recommend a dose escalation after observing a DLT. However, an
incoherent dose escalation results in an increase in dose by 50 mg/m2 after observing a DLT.
We now consider the performance of each approach across continuous and discrete scenarios, specif-
ically analysing accuracy index scores, mean bias, RMSE and mean number of DLTs; detailed results
tables are provided as supplementary material (Tables S1, S2, S3 and S4).
Table II. Coherence violation percentages (%) with SE over 1000
trials during increases in feasibility bound (TR design = 5 per trial;
Hybrid design = 20 per trial) for approaches that do not guarantee
coherence (continuous and discrete dose scenarios).
Continuous Discrete
Scenario Approach % SE % SE
1 TR 0.240 0.006 0 0
Hybrid (𝛼min = 0.10) 0.058 0.002 0.005 0.005
Hybrid (𝛼min = 0.25) 0.074 0.002 0 0
2 TR 0.320 0.007 0 0
Hybrid (𝛼min = 0.10) 0.032 0.001 0 0
Hybrid (𝛼min = 0.25) 0.063 0.002 0.005 0.005
3 TR 0.260 0.006 0 0
Hybrid (𝛼min = 0.10) 0.021 0.001 0 0
Hybrid (𝛼min = 0.25) 0.037 0.001 0 0
4 TR 0.340 0.007 0 0
Hybrid (𝛼min = 0.10) 0.042 0.001 0 0
Hybrid (𝛼min = 0.25) 0.032 0.001 0 0
5 TR 0.120 0.005 0 0
Hybrid (𝛼min = 0.10) 0.016 0.001 0 0
Hybrid (𝛼min = 0.25) 0.032 0.001 0 0
6 TR 0.420 0.007 0 0
Hybrid (𝛼min = 0.10) 0.032 0.001 0 0
Hybrid (𝛼min = 0.25) 0.068 0.002 0 0
7 TR 0.240 0.006 0.020 0.002
Hybrid (𝛼min = 0.10) 0.016 0.001 0 0
Hybrid (𝛼min = 0.25) 0.037 0.001 0 0
8 TR 0.240 0.006 0 0
Hybrid (𝛼min = 0.10) 0.026 0.001 0.005 0.005
Hybrid (𝛼min = 0.25) 0.026 0.001 0 0
9 TR 0.120 0.005 0 0
Hybrid (𝛼min = 0.10) 0.011 0.001 0 0
Hybrid (𝛼min = 0.25) 0.032 0.001 0 0
10 TR 0.100 0.004 0 0
Hybrid (𝛼min = 0.10) 0.032 0.001 0.005 0.005
Hybrid (𝛼min = 0.25) 0.021 0.001 0 0
SE, standard errors; TR, Tighiouart and Rogatko design.
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4.1. Continuous dose interval
Figures 2–5 show the performance of each approach across the continuous dose scenarios. Figure 2 shows
the EWOC approach with a median MTD estimator has much lower accuracy across most scenarios than
all other approaches, which typically score above 0.80. The remaining coherent approaches (EWOCwith
next dose MTD estimator, EAT and TDFB) have similar accuracy scores to those that do not guarantee
coherence (TR and Hybrid approaches).
Figure 3 shows the mean bias around MTD estimates, indicating that the EWOC approach tends to
lead to more biased results than approaches with escalating feasibility bounds; using the median MTD
estimator biases estimates above the truth, whereas the next dose estimator biases estimates below the
truth. Scenario 2 provides an exception to this trend; the gradual slope of the dose-toxicity curve and high
value of 𝜌0 = 0.30 mean that the most conservative escalation approaches (EWOC) perform better than
those that escalate the feasibility bound. Figure 4 shows all approaches that increase feasibility bounds
provide give lower RMSEs (except scenario 2) than the EWOC approach, and that performance differs
little between TR, Hybrid, EAT and TDFB.
Figure 2. Accuracy index scores for each approach applied to continuous dose interval scenarios. EAT, escalation
in the absence of toxicity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility bound;
TR, Tighiouart and Rogatko design.
Figure 3. Mean bias of maximum tolerated dose recommendations per approach for continuous dose scenarios.
Black dashed line indicates a mean bias of 0. EAT, escalation in the absence of toxicity; EWOC, escalation with
overdose control; TDFB, toxicity-dependent feasibility bound; TR, Tighiouart and Rogatko design.
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Figure 4. Root mean square error (RMSE) of maximum tolerated dose recommendations per approach for
continuous dose scenarios. Black dashed line indicates an RMSE of 0. EAT, escalation in the absence of toxic-
ity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility bound; TR, Tighiouart and
Rogatko design.
Figure 5. Mean number of dose-limiting toxicity (DLTs) per approach for continuous dose scenarios. EAT, esca-
lation in the absence of toxicity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility
bound; TR, Tighiouart and Rogatko design.
With respect to experimentation, Figure 5 shows fewer DLTs on average when using the EWOC
approach than all other approaches; the Hybrid and TDFB (𝛼min = 0.10) approaches give slightly lower
DLTs on average compared to TR, EAT and Hybrid and TDFB (𝛼min = 0.25). Furthermore, when increas-
ing the feasibility bound, the choice of 𝛼min does not have much impact on the percentage of patients
receiving doses with true probabilities of DLT in the [0.30, 0.35) interval, though there is a noticeable
difference in how much experimentation is conducted at the doses with the lowest DLT probabilities per
scenario (Table S1). Approaches with 𝛼min = 0.10 (Hybrid (𝛼min = 0.10), EAT and TDFB (𝛼min = 0.10))
exhibit more experimentation at lower doses (all but scenario 3, where the dose-toxicity curve is very
steep) compared with approaches with 𝛼min = 0.25, which is expected because a lower 𝛼min is used.
4.2. Discrete dose levels
We simulated 1000 trials as per the description in subsection 3.3, but now, the dose in LD closest
to H−1n
(
𝛼n+1
)
is used for experimentation and MTD recommendation when n = N. Figure 6 shows
the EWOC approach with median MTD estimator to have poor accuracy in the majority of scenarios.
© 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd Statist. Med. 2017
G. M. WHEELER, M. J. SWEETING AND A. P. MANDER
Figure 6. Accuracy index scores for each approach applied to discrete dose interval scenarios. EAT, escalation
in the absence of toxicity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility bound;
TR, Tighiouart and Rogatko design.
Figure 7. Mean bias of maximum tolerated dose recommendations per approach for discrete dose scenarios.
Black dashed line indicates a mean bias of 0. EAT, escalation in the absence of toxicity; EWOC, escalation with
overdose control; TDFB, toxicity-dependent feasibility bound; TR, Tighiouart and Rogatko design.
Furthermore, the TR, Hybrid, EAT and TDFB approaches have accuracy scores of at least 0.90 in 5 out of
10 scenarios, whereas both EWOC approaches only have exceed this threshold in 3 out of 10 scenarios.
When assessing the mean bias, Figure 7 shows the EWOC approaches are prone to positive and negative
bias more so than the other approaches, as observed in the continuous dose scenarios. Figure 8 shows the
approaches with escalating feasibility bounds have RMSEs clustered between 11.5 and 34.9, except for
scenario 2. For the EWOC approach with median MTD estimator, the RMSE tends to cluster around 40,
with no improvement in RMSE in scenario 2.
Figure 9 shows slightly fewer DLTs on average when using the EWOC approach than all other
approaches, as seen under continuous dose scenarios. All other approaches offer similar mean numbers
of DLTs. Whilst the EWOC approach doses fewer patients at overdoses, in scenarios 3–10, it also doses
the lowest percentage of patients at the MTD (Table S3); for scenarios 1 and 2, where the MTD is the
lowest dose level, the EWOC is the best performing approach (66.1% and 40.2% experimentation at
the MTD, respectively). Otherwise, amongst the approaches that guarantee coherent dose escalation, the
TDFB approach with 𝛼min = 0.25 and the EAT approach are the best performers (for scenarios 3–8 and
9–10, respectively). When including comparison to approaches that do not guarantee coherent escalation,
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Figure 8. Root mean square error (RMSE) of maximum tolerated dose recommendations per approach for
discrete dose scenarios. Black dashed line indicates an RMSE of 0. EAT, escalation in the absence of toxic-
ity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility bound; TR, Tighiouart and
Rogatko design.
Figure 9. Mean number of dose-limiting toxicity (DLTs) per approach for discrete dose scenarios. EAT, escalation
in the absence of toxicity; EWOC, escalation with overdose control; TDFB, toxicity-dependent feasibility bound;
TR, Tighiouart and Rogatko design.
the Hybrid design with 𝛼min = 0.25 provides slightly more experimentation at the MTD compared to the
TDFB approach with the same 𝛼min (0.2–1% across scenarios 3–10).
4.3. Sensitivity analyses
We also investigated the performance of each approach under model misspecification. Two true dose-
toxicity scenarios were generated from the power model 𝜋 (x∗; 𝛽) = (x∗)exp(𝛽) and hyperbolic tangent
model 𝜋 (x∗; 𝛽) =
(
tanh(x∗)+1
2
)exp(𝛽)
, assuming an MTD of 250mg/m2 (Figure S2 and Table S5); here
x∗ ∈ [0, 1] is the standardised dose mapped from x ∈
[
xmin, xmax
]
. We simulated 1000 trials as per
the description in subsection 3.3. Results for these simulations are provided as supplementary mate-
rial (Table S6 and Table S7 for continuous dose interval, Table S8 and Table S9 for discrete dose set).
We found that for both scenarios the EWOC approach with a fixed feasibility bound dosed the second-
highest proportion of patients close to the true MTD (beaten by TR design under power model scenario
and Hybrid (𝛼min = 0.25) under hyperbolic tangent model scenario), but dosed the lowest proportion
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of patients at overdoses. Coherence violations were observed under the TR and Hybrid designs. For
MTD recommendations, the EAT approach (under power model) and TDFB (𝛼min = 0.25) provided
most MTD recommendations in DLT probability interval [0.30, 0.35), though the TDFB (𝛼min = 0.25)
approach had the lowest mean bias in both scenarios. For discrete doses, all approaches exhibited similar
experimentation at the MTD, with the EWOC providing the lowest proportion of patients experienc-
ing overdoses. Coherence violations were only observed under the TR design. For recommendation, the
EWOC approach performed the worst, giving the lowest proportion of recommendations at the trueMTD
and the largest bias, regardless of MTD estimator. All other approaches performed similarly.
5. Discussion
In this paper, we investigated the operating characteristics of EWOC approaches that used fixed and vari-
able feasibility bounds to aid dose escalation and de-escalation decisions. Although some approaches for
increasing feasibility bounds mid-trial have been used in practice, they have not been studied in detail in a
comparative manner. Furthermore, increasing a feasibility bound regardless of DLT responses can lead to
incoherent dose-escalations; ideally, a dose-escalation approach that guarantees coherence in dose esca-
lation and de-escalation, whilst offering favourable operating characteristics regarding experimentation
andMTD recommendation, should be used. We proposed a TDFB approach to satisfy these requirements
and compared its performance with several dose-escalation approaches that either guarantee or do not
guarantee coherent dose escalation.
In our simulations, incoherent dose escalation occurred rarely; in scenarios 1–10 where doses were
selected from a continuous dose interval, the extent of incoherent escalation was not substantial (1 −
11 mg/m2), yet in the discrete dose scenarios, an incoherent escalation was an increase in dose by
50 mg/m2. Whilst the amounts witnessed here are not relatively large, Neuenschwander et al. [32]
describe a trial using the CRM inwhich, after observing twoDLTs in two patients at 25mg, themodel rec-
ommended dosing new patients at 40 mg, an increase of 60%; this was in part due to escalating from 10 to
25 mg and skipping two planned dose levels. Incoherent escalations may dissuade clinicians from using
EWOC-style approaches with increasing feasibility bounds and other model-based designs in practice.
Coherent escalation behaviour is rarely emphasised in the literature on dose escalation designs [20,
22, 23], yet by its definition it is a serious ethical issue. An ideal phase I trial design should aim to dose
as many patients at doses close to the TTL and recommend the correct MTD as often as possible for
future clinical trials. However, a practically useful design should be able to incorporate sensible dose-
escalation behaviour as well, so clinicians can be confident in implementing it in practice repeatedly on a
long-term basis. The coherent approaches studied in this paper require minimal extra effort to implement
in practice compared to approaches already used in trials that escalate the feasibility bound. Therefore,
a design that guarantees coherent dose escalation with comparable or superior operating characteristics
relative to existing approaches can and should be used.
The only approaches that guarantee coherence under the EWOC approach are the original EWOC
approach with fixed 𝛼, the EAT approach and the TDFB approach. In our simulation studies, both the EAT
and TDFB approaches showed comparable MTD recommendation percentages for doses around the TTL
relative to other approaches with increasing feasibility bounds, as well as similar bias and RMSE; this was
also the case for simulations conducted under two different forms of model misspecification. Both the
EAT and TDFB approaches offer comparable performance to approaches that do not guarantee coherent
dose escalation. It is interesting to note however that the EWOC approach seems to do moderately well
with respect to MTD recommendation when the true MTD is close to the extreme ends of the dose range.
However, the posterior medianMTD estimator is positively biased, whereas the next dose estimator tends
to be negatively biased. Therefore, using the posterior median MTD estimator under the original EWOC
approach is not advised, given the poor MTD recommendation accuracy.
A review of 1235 phase I cancer trials published between 1991 and 2006 showed only three trials
implemented an EWOC approach [7], whilst another review of phase I cancer trials published between
2007 and 2008 yielded no reported usage of the EWOC approach [1]. However, Rogatko and Tighiouart
[28] found 17 phase I trials that implemented EWOC approaches between 2001 and 2013, which shows
that the use of more advanced designs for phase I trials is slowly increasing. Several papers have identified
the primary reasons for the dearth of model-based dose-escalation methods in practice, and others have
attempted to provide useful recommendations for conducting adaptivemodel-based phase I trials [35–37].
We hope the descriptive and investigative work in this paper is used to improve the design of clinical
trials and to provide further guidance for using EWOC-based approaches in future phase I cancer trials.
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